Attached files
| file | filename |
|---|---|
| 10-Q - RADIENT PHARMACEUTICALS Corp | v203402_10q.htm |
| EX-31.2 - RADIENT PHARMACEUTICALS Corp | v203402_ex31-2.htm |
| EX-32.2 - RADIENT PHARMACEUTICALS Corp | v203402_ex32-2.htm |
| EX-31.1 - RADIENT PHARMACEUTICALS Corp | v203402_ex31-1.htm |
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002
In
connection with the Quarterly Report of Radient Pharmaceuticals Corporation (the
“Company”) on Form 10-Q for the period ending September 30, 2010, as
filed with the Securities and Exchange Commission on the date hereof (the
“Report’), I, Douglas MacLellan, President and Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company at the dates
and for the periods indicated.
|
Date:
November 22, 2010
|
/s/ Douglas MacLellan
|
|
|
Douglas
MacLellan
|
||
|
President
and Chief Executive Officer
(Principal
Executive Officer)
Radient
Pharmaceuticals Corporation
|
A signed
original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
This
certification accompanies this Quarterly Report on Form 10-Q pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the
extent required by such Act, be deemed filed by the Company for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). Such certification will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that the Company specifically incorporates it
by reference.